Skip to main content

The Skimune® platform (Skimune®Cosm; Skimune®Chem; Skimune®Mab) are unique non-artificial human in vitro skin tests

The Skimune® platform predicts hypersensitivity responses to pharmaceuticals including small molecule drugs and monoclonal antibodies, chemicals and cosmetics

Skimune® provides a pre-clinical predictive readout of skin damage which correlates with screening assays ie. cytokine release and T cell proliferation

Skimune®Mab is the only commercially available test for predicting adverse immune reactions to monoclonal antibodies, biobetters, biosimilars and antibody drug conjugates

The Skimune® platform tests are also used in dose response and efficacy studies for immunomodulatory drugs prior to Phase One clinical trials

The Skimune® 3D high throughput screening for the detection of sensitisation and toxicity to drugs, chemicals and cosmetics

Meet the team

Professor Anne Dickinson

Founder and Director

Anne’s research at Newcastle University led to the founding of Alcyomics in 2007. Due to her expertise in immunobiology she has developed human skin based in vitro assays for predicting clinical responses prior to clinical trial.

Dr Shaheda Ahmed

Scientific Manager

Dr Shaheda Ahmed is a Molecular biologist with expertise in skin explant assays and development of 3D tissue models.
Shaheda pursued her Post-Doctoral career at the University of Newcastle (UK) where she conducted research in Graft versus host disease (GvHD).
In 2009 she transitioned from academia to industry where she became a pivotal member of Alcyomics and played a direct role in supporting the advancement and development of the company.
Shaheda’s key focus has been on providing expertise in assay development and validation to expand the businesses' commercial sector, in addition to contributing to the R&D strategy to advance the company’s wider commercial strategy, to help support the growth and development of the business. Shaheda has since progressed to successfully heading the technical team in both departments as Scientific Manager.

Dr Margaret Anne Craig

Chief Commercial Officer

Dr Margaret Anne Craig brings a wealth of knowledge from both scientific and business backgrounds; from co-founding and running Clyde Biosciences Ltd as CEO for 4 years (securing £2m of venture funding in 2015) to being awarded a BBSRC/RSE Enterprise Fellowship and being a recipient of the prestigious Royal Academy of Engineering UK Entrepreneur of the Year award for 2012. In 2016 Margaret Anne took on the role of Chief Commercial Officer of Stem Cell and Devices Laboratory in Japan globally commercialising Nobel Prize winning stem cell technology from Kyoto University and went on to secure £5m of Series B funding. She has since gone on to work as a business development and strategic advisor to other companies in Japan and the UK before taking on the Chief Commercial Officer role at Alcyomics

  • This form collects your name and email so what we can add your to our newsletter list and send you relevant updates via email. Read our privacy policy for details on how we manage your data.